One-time device cost + monthly subscription. Details below.

We will be selling the device for an estimated $50-$60, which requires a subscription to our mobile app at a cost of $20-$100 / per month depending on the level of smoker you are. This subscription will also include free replacement capsules that will be sent automatically to the user. The pricing is based on what cigarette and vape smokers are currently paying in the market for cigarettes, pens, pods and/or nicotine replacement therapies such as Nicorette gum.

There are currently 51 million smokers and e-cig users in the US & UK with 33 million of them actively trying to quit. Capturing a fraction of this market, 4%, with an average user on our pricing model, including churn, leads us to approximately $400,000,000 in ARR with $40,000,000 in yearly device sales - and a clear path to a multi-billion dollar opportunity.

If you look at comparative products such as Chantix, Nicorette and Nicoderm - they are all doing billions in revenue yearly and they are horrible side effects and low success rates. We anticipate having a much higher quit success rate with minimal side effects, so it's entirely possible we disrupt these products and take over the market.

Current nicotine replacement therapies such as Nicorette, Nicoderm, and Chantix have low cessation success rates (8-11%) because they don’t handle the most important variables in smoking cessation; self-control and nicotine delivery. They put the onus on the patient to manually dose themselves down and don’t deliver nicotine as rapidly as a cigarette - this increases withdrawal symptoms and relapse rates. 

Furthermore, these other solutions don’t give smokers what they’re used to: specifically oral fixation, smoke inhalation or custom physiological satiation (easy to give up at anytime). We can tailor each individual’s use accordingly with no patient input no matter the situation or addiction level - allowing them to completely forget about the cessation process, and driving the highest cessation success rate in the market. 

With Hale, there’s no more chewing gums. No ugly patches. No dosing yourself down. No pills. Just smoke whenever and however you want, and pay us less than you would pay for any other cessation solution. 

Once approved for sale by the FDA, we can make claims of cessation that no other vaporizer on the market can legally make. For other NRT (nicotine replacement therapy) forms, such as Nicorette, that can make cessation claims their numbers are so low that touting them would actually be a detriment to their brand. If we execute, our marketing would be centered around being the first FDA approved vaporizer device for smoking cessation and/or nicotine de-addiction and our ability to accomplish it, i.e. "Hale's vaporizer system is 50% more effective at nicotine de-addiction than the leading nicotine replacement therapies on the market", or "1 in 3 cigarette smokers are able to quit in 8 weeks after using Hale." Those are powerful statements that can only be made after going through a regulatory process.

Using those statements, and our branding, we will use online and traditional channels (TV/radio/billboards) to get the word out about how to help people end their addiction. We'd also look to partner with organizations such as Truth, rehabilitation centers (a lot of addicts are cigarette smokers), and even corporations (smokers cost co's $6k+ a year).

On a separate note, if we are approved for Rx for under 21, we can push this through medical practitioner offices. We've already heard from a number of doctors that parents are coming in and asking for ways to help their kid quit e-cigs, we would be the only solution a doctor could professionally suggest.